Vision correction surgery trial to study both eyes
This article was originally published in Clinica
Executive Summary
US vision correction company Refractec is to begin treating both eyes of patients on the same day with its conductive keratoplasty (CKT) technique as part of a modified clinical trial of hyperopia correction. The US FDA approved the change to the Phase III trial based on hyperopic stability data during a one to nine month follow-up, which were equal to or better than that of competitors in the field, according to the Irvine, California-based company.
You may also be interested in...
What To Consider For German Orphan Drug Price Negotiations
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Viatris’ UpJohn Breaking Taboo Around Erectile Dysfunction With UK PR Campaign
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Top 100 Outlook 2021: Medtechs Look To Build On Experiences Of Serving Global Markets In A Pandemic
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Need a specific report? 1000+ reports available
Buy Reports